Loading
Palatin Technologies Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Jun 2025.
Palatin Technologies Inc: what insiders have been doing
Palatin Technologies Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 15 filings were filed, from 4 insiders.
There is no open-market purchase to report; the filings show 1 sale worth €8,020 by 1 insider. One trade stands out by size: a sale of €8,020 from Wills Stephen T, disclosed on 29 December 2025.
With 15 filings in twelve months, the company is quieter than the median of 19 filings across the 5,810 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 5 purchases and 6 sales. For the fiscal year to 30 June 2026, the annual 10-K puts revenue at 8.8 m USD and net income at -8.4 m USD.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
77
Thresholds
n/a
Buy Volume
€197M
5 ops. · all time
Sell Volume
€22,263
6 ops. · all time
Who traded when
BuySaleStephen T. Wills1 buy1 sale
Alan W. Dunton1 buy
Carl Spana1 buy
ROBERT K. DEVEER Jr.1 buy
Since the insiders bought
- +56.3%Entry US$7.50 · Close at T+365 US$11.72
- +56.3%Entry US$7.50 · Close at T+365 US$11.72
- +267.8%Entry US$4.50 · Close at T+365 US$16.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Palatin Technologies Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$53.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
US$8.19
Analyst consensus
3 analystsStrong buy
US$47.50Target US$53.50(+553%)US$60.00
Income statement
EBITDA-US$17M
Net income-US$17.3M-63.5% margin
Valuation
PER (trailing)91.2x
PER (forward)-4.4x
P/Book2.2x
Beta-0.01
Balance sheet & cash
Market capUS$14.6M
Total debtUS$163.8k
Free Cash Flow-US$21.3M
Debt / Equity3%
Profitability & ownership
ROE-877.5%
ROA-91.9%
% insiders8.1%
% institutions50.1%
Last declaration on 17 July 2026
Declarations77 total
22 shares@ US$11.770.0015% mcap0.4% of flowCommon StockSEC:0001493152-26-033742:0
94 shares@ US$14.340.0077% mcap1.9% of flowCommon StockSEC:0001493152-26-033742:2
33 shares@ US$11.770.0022% mcap0.0% of flowCommon StockSEC:0001493152-26-033745:0
119 shares@ US$11.720.0079% mcap0.0% of flowCommon StockSEC:0001493152-26-033745:1
79 shares@ US$11.720.0053% mcap1.3% of flowCommon StockSEC:0001493152-26-033742:1
142 shares@ US$14.340.012% mcap0.0% of flowCommon StockSEC:0001493152-26-033745:2
26 shares@ US$21.380.8% of flowCommon StockSEC:0001493152-26-000132:0
40 shares@ US$21.380.0% of flowCommon StockSEC:0001493152-26-000130:0
565 shares@ US$16.744313.0% of flowCommon StockSEC:0001493152-25-029385:0
1,300 shares0Common StockSEC:0001493152-25-027268:0
1,000 shares0Common StockSEC:0001493152-25-027267:0
95 shares0Common StockSEC:0001493152-25-027272:0
110 shares0Common StockSEC:0001493152-25-027269:0
33 shares@ US$8.000.4% of flowCommon StockSEC:0001654954-25-013237:0
51 shares@ US$8.000.0% of flowCommon StockSEC:0001654954-25-013235:0
1,500 shares@ €129,307.5048100.0% of flowSeries D Preferred StockSEC:0001654954-25-007107:0
Canonical exit: 11 Sept 2025 (T+90)
1,500 shares@ US$150,000.0099.9% of flowSeries D Preferred StockSEC:0001654954-25-007106:0
Canonical exit: 11 Sept 2025 (T+90)
200 shares@ US$20,000.0099.8% of flowSeries D Preferred StockSEC:0001654954-25-007105:0
Canonical exit: 11 Sept 2025 (T+90)
100,000 shares@ US$0.101837.6% of flowCommon StockSEC:0001654954-25-005457:0
Canonical exit: 5 Aug 2025 (T+90)
2,499 shares@ US$1.666.2% of flowCommon StockSEC:0001654954-24-009894:0
1,527 shares@ US$1.824.2% of flowCommon StockSEC:0001654954-24-009703:0
2,331 shares@ US$1.820.0% of flowCommon StockSEC:0001654954-24-009702:0
12,000 shares0Common StockSEC:0001654954-24-009045:0
69,000 shares0Common StockSEC:0001654954-24-009000:0
12,000 shares0Common StockSEC:0001654954-24-008999:0
25 of 77 declarations
About Palatin Technologies Inc
Palatin Technologies Inc. (ticker PTN) is a U.S.-based biopharmaceutical company quoted on the NYSE American market in the United States, with its main executive office in Princeton, New Jersey. For French-speaking investors, Palatin is best understood as a specialty clinical-stage biotech focused on the melanocortin receptor system, a biological pathway that influences appetite, metabolism, inflammation, and certain immune responses. The company positions itself as a developer of first-in-class medicines aimed at diseases with meaningful unmet medical need and commercial potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/ptn_10k.htm))
Palatin was founded in the 1990s and has built a long-standing niche around melanocortin biology. Its leadership has been remarkably stable, with co-founder and CEO Carl Spana serving in senior management for decades. The company’s core strategy is typical of a development-stage biotech: advance internally generated assets through preclinical and clinical milestones, then seek to create value through strategic collaborations, licensing agreements, or other partnering arrangements with larger pharmaceutical groups. ([palatin.com](https://palatin.com/about-us/?utm_source=openai))
Read moreShow less
The current pipeline is centered on MC4R agonists, including peptides and small molecules designed for obesity, metabolic disorders, and rare MC4R-pathway diseases such as hypothalamic obesity and Prader-Willi syndrome. Palatin is also developing MC1R agonist programs with potential applications in inflammatory and autoimmune diseases, including dry eye disease, uveitis, diabetic retinopathy, and inflammatory bowel disease. Historically, the company also had a commercial product, Vyleesi®, which was approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women; however, that asset was divested to Cosette Pharmaceuticals in 2023. ([sec.gov](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/ptn_10k.htm))
From a competitive standpoint, Palatin remains a small-cap, high-risk, high-upside biotech rather than a commercial-stage pharmaceutical company. Its investment case depends on the scientific and clinical differentiation of its melanocortin platform versus much larger competitors active in obesity, ophthalmology, and immunology. The upside is that Palatin’s approach is targeted and potentially novel; the downside is the usual biotech constraints: limited resources, clinical/regulatory uncertainty, and the need for repeated external financing. The company’s most recent annual report explicitly highlights accumulated losses, modest cash balances, and the need for additional capital to continue its development plan. ([sec.gov](https://www.sec.gov/Archives/edgar/data/911216/000165495425011030/ptn_10k.htm))
Recent news has been constructive at the program level. Palatin has been advancing PL7737, an oral MC4R agonist for obesity, with IND and clinical initiation plans outlined for 2026, and it announced a global research collaboration and license agreement with Boehringer Ingelheim in August 2025 aimed at retinal disease. The company also completed multiple equity financings to support operations and, according to its filings, experienced listing and trading changes during 2025, including a period on OTCQB after the NYSE American listing was interrupted. ([palatin.com](https://palatin.com/press_releases/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
